ATE491721T1 - Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten - Google Patents

Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten

Info

Publication number
ATE491721T1
ATE491721T1 AT98945134T AT98945134T ATE491721T1 AT E491721 T1 ATE491721 T1 AT E491721T1 AT 98945134 T AT98945134 T AT 98945134T AT 98945134 T AT98945134 T AT 98945134T AT E491721 T1 ATE491721 T1 AT E491721T1
Authority
AT
Austria
Prior art keywords
formation
protein aggregates
fibriles
amyloid
composition
Prior art date
Application number
AT98945134T
Other languages
English (en)
Inventor
Erich Wanker
Hans Lehrach
Eberhard Scherzinger
Gillian Bates
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE491721T1 publication Critical patent/ATE491721T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98945134T 1997-08-01 1998-07-31 Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten ATE491721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97113306 1997-08-01
PCT/EP1998/004811 WO1999006545A2 (en) 1997-08-01 1998-07-31 Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation

Publications (1)

Publication Number Publication Date
ATE491721T1 true ATE491721T1 (de) 2011-01-15

Family

ID=8227161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945134T ATE491721T1 (de) 1997-08-01 1998-07-31 Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten

Country Status (5)

Country Link
US (1) US7078191B1 (de)
EP (1) EP1001987B1 (de)
AT (1) ATE491721T1 (de)
DE (1) DE69842048D1 (de)
WO (1) WO1999006545A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) * 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7595199B1 (en) 1998-07-31 2009-09-29 Max-Planck-Gesellschaft zur Förderung der Wissenchaften e.V. Method of detecting amyloid-like fibrils or protein aggregates
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU5602100A (en) * 1999-06-09 2000-12-28 Arch Development Corporation Recombinant prion-like genes and proteins and materials and methods comprising same
AU7766300A (en) * 1999-10-07 2001-05-10 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulatingsame
AU4819101A (en) * 2000-04-13 2001-10-30 University Of British Columbia, The Modulating cell survival by modulating huntingtin function
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP1366368A2 (de) * 2001-01-03 2003-12-03 Ortho-Mcneil Pharmaceutical, Inc. Alpha-synuklein-anhäufungsassays
US7045290B2 (en) 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US6846640B2 (en) 2002-04-30 2005-01-25 Pharmacia & Upjohn Company Time-resolved fluorescence assay for the detection of multimeric forms of A-beta 1-40
KR20050053607A (ko) * 2002-08-07 2005-06-08 유니버시티 오브 델라웨어 단백질 오조립 및 응집을 나타내는 질병을 치료하기 위한조성물 및 방법
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CA2528627A1 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
WO2006138160A2 (en) * 2005-06-16 2006-12-28 The Regents Of The University Of California Amyloid beta protein channel structure and uses thereof indentifying potential drug molecules for neurodegenerative diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2010009415A1 (en) 2008-07-18 2010-01-21 Canon U.S. Life Sciences, Inc. Methods and systems for microfluidic dna sample preparation
US8304185B2 (en) 2009-07-17 2012-11-06 Canon U.S. Life Sciences, Inc. Methods and systems for DNA isolation on a microfluidic device
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP2013540720A (ja) * 2010-09-01 2013-11-07 コヨーテ・ファーマシューティカルズ・インコーポレイテッド 神経変性疾患の処置のための方法
KR102181440B1 (ko) * 2019-06-07 2020-11-23 한국과학기술원 티오블라빈-티(ThT)가 결합된 자기조립형 아밀로이드 하이브리드 나노구조체 및 이를 이용한 인공광합성 방법
CN115825023B (zh) * 2022-10-08 2025-05-16 河南工业大学 一种淀粉样纤维蛋白含量的测定方法
CN121499820A (zh) * 2026-01-12 2026-02-10 美康生物科技股份有限公司 一种抗多聚体干扰的血清游离λ轻链检测试剂、试剂盒和检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516081D0 (en) 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
NZ224663A (en) * 1987-05-28 1990-11-27 Amrad Corp Ltd Fusion proteins containing glutathione-s-transferase and expression of foreign polypeptides using glutathione-s-transferase encoding vectors
US5234814A (en) 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
EP0758393A1 (de) 1994-04-26 1997-02-19 PHARMACIA & UPJOHN COMPANY I-domäne des proteins mac-1, ihre verwendung zur blockierung der adhäsion von neutrophilen
AU8083094A (en) 1994-10-19 1996-05-15 General Hospital Corporation, The A diagnostic assay for alzheimer's disease: assessment of abeta abnormalities
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US5723301A (en) * 1995-11-03 1998-03-03 Duke University Method to screen compounds that affect GAPDH binding to polyglutamine
FR2741088B1 (fr) * 1995-11-10 1998-01-30 Centre Nat Rech Scient Methode de traitement de maladies neurodegeneratives mettant en oeuvre un anticorps ic2, un fragment ou derive de celui-ci et compositions pharmaceutiques correspondantes
AU4725597A (en) * 1996-10-30 1998-05-22 Srl Inc. Cdna fragments of gene causative of spinocerebellar ataxia type
GB9701045D0 (en) 1997-01-18 1997-03-05 Narang Harash K Diagnosis of neuro-degenerative disorders

Also Published As

Publication number Publication date
EP1001987A2 (de) 2000-05-24
US7078191B1 (en) 2006-07-18
WO1999006545A2 (en) 1999-02-11
WO1999006545A3 (en) 1999-08-05
EP1001987B1 (de) 2010-12-15
DE69842048D1 (de) 2011-01-27
WO1999006545A8 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
ATE491721T1 (de) Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten
ATE300052T1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
DE69525847D1 (de) Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
EP1140964A4 (de) Teilstücke des bindegewebe wachstumsfaktors und verfahren und verwendungen davon
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
RU95106649A (ru) Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
DE69611251D1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE554784T1 (de) Hochaffiner ligand für p75 neurotrophin-rezeptor
EP1139752A4 (de) Verfahren und zusammensetzungen zur behandlung von zellproliferationsstörungen
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
ATE367815T1 (de) Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension
ATE473294T1 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
DE69523586D1 (de) Verfahren zum screening für die erkrankung crohn durch die verwendung von tnf-mikrosatelliten allelen
CO5460266A1 (es) Novedosos analogos de la somatostatina
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69725457D1 (de) Piperazinderivate als neurokinin-antagonisten
ATE290871T1 (de) Verfahren zur behandlung navikularer krankheiten bei pferden
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
Wu et al. Intervertebral disc collagen: usage of the short form of the α1 (IX) chain in bovine nucleus pulposus
DE60016405D1 (de) Neurodegenerative-erkrankung verwandtes gen
DE69534251D1 (de) Xanthin derivate verbindungen zur aktivierung der chlorid-leitung in tierzellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties